NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
- Mechanism
- Curator reviewed
NGX267 has been shown to stimulate M1 receptors in a fashion analogous to acetylcholine, a neurotransmitter essential for memory and cognitive function that is depleted when neurons, or brain cells, degenerate. The M1 receptor plays an important role in memory and cognitive processing. Its activation has also been linked to decreases in two biochemical processes, AB production and tau protein phosphorylation, both of which are involved in the creation of the neurofibrillary tangles and amyloidplaques that are major histopathological hallmarks of Alzheimer's disease. By selectively enhancing M1 cholinergic neurotransmission in the brain, NGX267 may offer advantages over current therapies for Alzheimer's disease due to the relative preservation of this system in patients who are clinically symptomatic.
- Primary indication
- Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.Curator reviewed
- Formula / weight
- C10H18N2OS · 214.33 g/mol (avg)
- Code names
- AF-267B · NGX-267
Resolves to
PHOZOHFUXHPOCK-QMMMGPOBSA-NSMILESCC[C@@H]1SC2(CCN(C)CC2)NC1=OWhat you can answer from here — as of January 29, 2025
Which drugs share a target with NGX267, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account